NCT04450953View on ClinicalTrials.gov

The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients.

PHASE3RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Kidney Transplantation for More Than One YearPatients with a Kidney Transplantation on Cyclosporine
Interventions
DRUG

Eplerenone 50mg/day (cross over design)

Eplerenone 50mg/day for 6 months followed

OTHER

Period without eplerenone (cross over design)

6-month period without eplerenone

Trial Locations (1)

54500

RECRUITING

CHRU de Nancy, Vandœuvre-lès-Nancy

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER